biomarkers – mycolab.ai

Special Issue: Marine-Derived Compounds Applied in Cardiovascular Disease

mycolabadmin

This collection of studies explores how compounds from ocean sources like seaweed, fish, shrimp, and microalgae can help protect heart health and prevent cardiovascular diseases. Researchers examined various marine ingredients and found they can reduce inflammation, lower cholesterol, reduce blood pressure, and prevent blood clots. The findings suggest that marine-derived products could become safer, more affordable alternatives or complements to current heart disease medications while supporting sustainable ocean resource use.

Prognostic model for gastric cancer patients with COVID-19 and network pharmacology study on treatment by lentinan

mycolabadmin

This study investigated how lentinan, a compound from shiitake mushrooms, might help treat patients who have both gastric cancer and COVID-19. Researchers identified five genes that predict patient outcomes and found that lentinan may work by controlling immune cell activity and reducing inflammation. The study suggests lentinan could be a useful additional treatment for this challenging combination of diseases, though more research is needed.

Editorial: Raising the bar: advancing therapeutic strategies for fighting communicable and noncommunicable diseases

mycolabadmin

Scientists are developing new ways to fight dangerous infections caused by bacteria, viruses, and drug-resistant pathogens. Recent discoveries include safer uses of existing drugs, better dosing strategies tailored to individual patients, and effective combination therapies that reduce antibiotic resistance. These advances represent important progress in treating serious infectious diseases like COVID-19, tuberculosis, and bacterial infections.

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine

mycolabadmin

This review examines how psychedelic drugs like ketamine, MDMA, and psilocybin could offer new hope for people with PTSD by working on the brain differently than current medications. These compounds work quickly and help the brain form new neural connections that can help people process traumatic memories more effectively. When combined with therapy, these drugs show promise in reducing PTSD symptoms faster and more effectively than traditional antidepressants. The review also explains how doctors could use personalized medicine approaches using brain scans and genetic testing to determine which treatment would work best for each individual patient.

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review

mycolabadmin

This review examines how scientists can predict which patients will benefit most from psychedelic-assisted therapy for depression by measuring biological markers in the brain and blood. Researchers found that certain brain changes and protein levels—particularly involving the amygdala, specific brain regions, and inflammation markers—appear linked to treatment success. While the current studies are small, they suggest that measuring these biological markers could eventually help doctors personalize psychedelic treatments for depression.

Identification of Blood Biomarkers of Psilocybin-Assisted Therapy Treatment Response for Generalised Anxiety Disorder

mycolabadmin

Researchers studied how psilocybin-assisted therapy works for people with anxiety disorders by examining blood samples from patients who responded well to treatment versus those who didn’t. They identified four genes whose expression patterns could help predict which anxiety patients would benefit from psilocybin therapy before starting treatment. This breakthrough could help doctors avoid giving intensive treatment to patients unlikely to respond and instead direct them toward more effective alternatives.

The Gut Mycobiome for Precision Medicine

mycolabadmin

This comprehensive review explores how fungi in our gut play important roles in our health and disease. While fungi make up only a tiny fraction of our gut microbiota, they have outsized effects on conditions like diabetes, inflammatory bowel disease, and even certain cancers. The review discusses how scientists study these fungi and how understanding individual fungal profiles could lead to personalized medical treatments tailored to each person’s unique microbial makeup.

Refractory fungal infection: Three case reports highlighting good practice

mycolabadmin

This case series examines three patients with serious fungal infections that did not respond well to standard antifungal treatments. The cases demonstrate how fungi can develop resistance to common antifungal drugs like azoles, making infections harder to treat. The authors emphasize that accurate identification of the fungus, testing its sensitivity to drugs, monitoring drug levels in the blood, and careful use of antifungal medications are essential for successfully treating these difficult infections.

Diagnostic Approaches to Invasive Candidiasis: Challenges and New Perspectives

mycolabadmin

Invasive candidiasis is a serious fungal infection affecting critically ill patients in hospitals. Current testing methods like blood cultures are slow and sometimes miss the infection. Researchers are developing faster diagnostic tests using DNA detection and biomarkers that can identify infections within hours instead of days, allowing doctors to start treatment sooner and save more lives.

Photo Quiz: A cutaneous fungal infection with discordant biomarker results—a diagnostic challenge

mycolabadmin

A woman with advanced HIV infection presented with skin sores and respiratory symptoms that were initially suspected to be a viral infection. Testing revealed she had histoplasmosis, a serious fungal infection caused by Histoplasma capsulatum that had spread throughout her body affecting her skin, lungs, and lymph nodes. While standard tests for this fungus were negative, other fungal markers and cultures eventually confirmed the diagnosis, and she was treated with antifungal medications.

Research Keyword: biomarkers